**The FDA's July 23, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommended adding BPC-157 to the 503A bulk drug substances list for a specific indication, following its April 2026 removal from Category 2 after withdrawn nominations.** This non-binding advisory step occurred against FDA staff recommendations citing insufficient human safety and efficacy data, primarily immunogenicity risks, peptide impurities, and minimal clinical evidence limited to small or outdated studies. Formal inclusion on the 503A bulks list requires agency rulemaking with notice-and-comment periods, typically spanning many months to over a year, before compounding pharmacies could lawfully use it under prescription. Trader sentiment reflects the committee outcome raising probabilities of eventual Category 1 status while accounting for procedural delays, evidentiary concerns, and potential shifts in final FDA determination. No further agency action has occurred as of late August 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedNEW
Aug 31, 2026
August 31, 2026
4%
December 31, 2026
51%
$3,486 Vol.
August 31, 2026
$1,754 Vol.
4%
December 31, 2026
$1,733 Vol.
51%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**The FDA's July 23, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommended adding BPC-157 to the 503A bulk drug substances list for a specific indication, following its April 2026 removal from Category 2 after withdrawn nominations.** This non-binding advisory step occurred against FDA staff recommendations citing insufficient human safety and efficacy data, primarily immunogenicity risks, peptide impurities, and minimal clinical evidence limited to small or outdated studies. Formal inclusion on the 503A bulks list requires agency rulemaking with notice-and-comment periods, typically spanning many months to over a year, before compounding pharmacies could lawfully use it under prescription. Trader sentiment reflects the committee outcome raising probabilities of eventual Category 1 status while accounting for procedural delays, evidentiary concerns, and potential shifts in final FDA determination. No further agency action has occurred as of late August 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Market Opened: Jun 22, 2026, 10:10 PM ET
Volume
$3,486End Date
Jan 1, 2027Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**The FDA's July 23, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommended adding BPC-157 to the 503A bulk drug substances list for a specific indication, following its April 2026 removal from Category 2 after withdrawn nominations.** This non-binding advisory step occurred against FDA staff recommendations citing insufficient human safety and efficacy data, primarily immunogenicity risks, peptide impurities, and minimal clinical evidence limited to small or outdated studies. Formal inclusion on the 503A bulks list requires agency rulemaking with notice-and-comment periods, typically spanning many months to over a year, before compounding pharmacies could lawfully use it under prescription. Trader sentiment reflects the committee outcome raising probabilities of eventual Category 1 status while accounting for procedural delays, evidentiary concerns, and potential shifts in final FDA determination. No further agency action has occurred as of late August 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$3,486End Date
Jan 1, 2027Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...**The FDA's July 23, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommended adding BPC-157 to the 503A bulk drug substances list for a specific indication, following its April 2026 removal from Category 2 after withdrawn nominations.** This non-binding advisory step occurred against FDA staff recommendations citing insufficient human safety and efficacy data, primarily immunogenicity risks, peptide impurities, and minimal clinical evidence limited to small or outdated studies. Formal inclusion on the 503A bulks list requires agency rulemaking with notice-and-comment periods, typically spanning many months to over a year, before compounding pharmacies could lawfully use it under prescription. Trader sentiment reflects the committee outcome raising probabilities of eventual Category 1 status while accounting for procedural delays, evidentiary concerns, and potential shifts in final FDA determination. No further agency action has occurred as of late August 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions